Publications by authors named "Wei-Lin Cheng"

Objective: To address the challenge of assessing sedation status in critically ill patients in the intensive care unit (ICU), we aimed to develop a non-contact automatic classifier of agitation using artificial intelligence and deep learning.

Methods: We collected the video recordings of ICU patients and cut them into 30-second (30-s) and 2-second (2-s) segments. All of the segments were annotated with the status of agitation as "Attention" and "Non-attention".

View Article and Find Full Text PDF

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by the degeneration of motor neurons in the spinal cord, leading to muscular atrophy. SMA is caused by deletions or mutations in the survival motor neuron gene (SMN1) on chromosome 5q13. A second copy of the SMN gene (SMN2) also exists on chromosome 5, and both genes can produce functional protein.

View Article and Find Full Text PDF

We previously reported 4-(3-((6-bromonaphthalen-2-yl)oxy)-2-hydroxypropyl)-N,N-dimethylpiperazine-1-sulfonamide (1) as a novel heat shock protein 90 inhibitor with moderate activity. In our ongoing efforts for the discovery of Hsp90 modulators we undertake structural investigations on 1. Series of the titled compound were designed, synthesized and evaluated.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Wei-Lin Cheng"

  • - Wei-Lin Cheng's recent research emphasizes the development of advanced medical technologies, including a deep learning-based automated ICU agitation monitoring system that aims to enhance patient care by providing accurate assessments of sedation in critically ill patients.
  • - Cheng's work also explores the biochemical aspects of spinal muscular atrophy (SMA), examining the role of securinine in enhancing the inclusion of SMN2 exon 7, which could have significant implications for treatment strategies of this neurodegenerative disease.
  • - Furthermore, the author has contributed to medicinal chemistry by investigating novel derivatives as inhibitors of heat shock protein 90 (Hsp90), focusing on structural modifications to improve their therapeutic potential, highlighting the continuous search for effective cancer treatments.